Incannex wins US patent for IHL-42X obstructive sleep apnea treatment, expiry 2040
IXHL•US patent covers IHL-42X composition and treatment methods
- Incannex won a U.S. patent covering the IHL-42X composition and methods of treatment for obstructive sleep apnea.
- The patent carries a baseline expiry of July 9, 2040.
- Incannex is assessing eligibility for patent term extension if IHL-42X later wins marketing approval.
